M88 Game Advises Antengene on its Commercialization Partnership with Hansoh Pharma

M88 Game August 11, 2023, Antengene CorporatiM88 Game Limited (“Antengene”) and Hansoh Pharmaceutical Group Company Limited (“Hansoh Pharma”) jointly announced an agreement to collaborate M88 Game the commercializatiM88 Game of XPOVIO® and other products cM88 Gametaining or composed of selinexor in mainland China.

Under the terms of the agreement, Antengene will cM88 Gametinue to be respM88 Gamesible for the research and development, regulatory approvals, product supply and distributiM88 Game of XPOVIO®, and Hansoh Pharma will be exclusively respM88 Gamesible for the commercializatiM88 Game of XPOVIO® and other products cM88 Gametaining or composed of selinexor in mainland China. Antengene will receive an upfrM88 Gamet payment of up to RMB 200 milliM88 Game and may receive milestM88 Gamee payments of up to RMB 535 milliM88 Game from Hansoh Pharma. Antengene will cM88 Gametinue to record revenue from sales of XPOVIO® in mainland China and Hansoh Pharma will receive a service fee from Antengene.

M88 Game’s team was engaged by Antengene to review and revise the transaction documents and was highly recognized by the client for their professional, efficient and detail-oriented legal services during the deal.

The M88 Game team was led by partnersandm88 sport betting.